Movement Alert｜Tempus AI Rises 5.05% in Regular Trading, FDA Clears AI-Powered Pulmonary Hypertension Detection Device

Market Focus

Yesterday

On August 25, Tempus AI rose 5.05% in regular trading, trading at $69.435/share, with turnover of $234 million. The rally was driven by the announcement that the company's AI software device, Tempus ECG-PH, received 510(k) clearance from the U.S. Food and Drug Administration.

The cleared device analyzes standard 12-lead electrocardiograms for signs associated with pulmonary hypertension. It is indicated for use in patients aged 40 and older who present cardiovascular symptoms but have no known history of the disease. By leveraging AI to detect subtle ECG abnormalities linked to pulmonary hypertension, the tool aims to improve early-stage screening efficiency and provide clinicians with more precise diagnostic support.

The FDA clearance marks a significant commercialization milestone for Tempus AI in the cardiovascular diagnostics space. The company, which primarily operates in precision medicine through genomic sequencing, data analytics, and clinical trial matching services, has indicated plans to further expand its AI-driven solutions across broader healthcare applications.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/news/1106547212"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106547212\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106547212?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-25 22:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106547212","market":"us","top_or_hot":-1,"title":"Movement Alert｜Tempus AI Rises 5.05% in Regular Trading, FDA Clears AI-Powered Pulmonary Hypertension Detection Device","media":"Market Focus","content":"<p><p>On August 25, Tempus AI rose 5.05% in regular trading, trading at $69.435/share, with turnover of $234 million. The rally was driven by the announcement that the company's AI software device, Tempus ECG-PH, received 510(k) clearance from the U.S. Food and Drug Administration.</p><p>The cleared device analyzes standard 12-lead electrocardiograms for signs associated with pulmonary hypertension. It is indicated for use in patients aged 40 and older who present cardiovascular symptoms but have no known history of the disease. By leveraging AI to detect subtle ECG abnormalities linked to pulmonary hypertension, the tool aims to improve early-stage screening efficiency and provide clinicians with more precise diagnostic support.</p><p>The FDA clearance marks a significant commercialization milestone for Tempus AI in the cardiovascular diagnostics space. The company, which primarily operates in precision medicine through genomic sequencing, data analytics, and clinical trial matching services, has indicated plans to further expand its AI-driven solutions across broader healthcare applications.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Tempus AI Rises 5.05% in Regular Trading, FDA Clears AI-Powered Pulmonary Hypertension Detection Device</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Tempus AI Rises 5.05% in Regular Trading, FDA Clears AI-Powered Pulmonary Hypertension Detection Device\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-25 22:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 25, Tempus AI rose 5.05% in regular trading, trading at $69.435/share, with turnover of $234 million. The rally was driven by the announcement that the company's AI software device, Tempus ECG-PH, received 510(k) clearance from the U.S. Food and Drug Administration.</p><p>The cleared device analyzes standard 12-lead electrocardiograms for signs associated with pulmonary hypertension. It is indicated for use in patients aged 40 and older who present cardiovascular symptoms but have no known history of the disease. By leveraging AI to detect subtle ECG abnormalities linked to pulmonary hypertension, the tool aims to improve early-stage screening efficiency and provide clinicians with more precise diagnostic support.</p><p>The FDA clearance marks a significant commercialization milestone for Tempus AI in the cardiovascular diagnostics space. The company, which primarily operates in precision medicine through genomic sequencing, data analytics, and clinical trial matching services, has indicated plans to further expand its AI-driven solutions across broader healthcare applications.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"","article_id":"1106547212","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106547212","pubTimestamp":1787668901,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 25, Tempus AI rose 5.05% in regular trading, trading at $69.435/share, with turnover of $234 million. The rally was driven by the announcement that the company's AI software device, Tempus...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"动向提醒|Tempus AI常规交易上涨5.05%，FDA批准人工智能肺动脉高压检测设备","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1},"content_text":"On August 25, Tempus AI rose 5.05% in regular trading, trading at $69.435/share, with turnover of $234 million. The rally was driven by the announcement that the company's AI software device, Tempus ECG-PH, received 510(k) clearance from the U.S. Food and Drug Administration.The cleared device analyzes standard 12-lead electrocardiograms for signs associated with pulmonary hypertension. It is indicated for use in patients aged 40 and older who present cardiovascular symptoms but have no known history of the disease. By leveraging AI to detect subtle ECG abnormalities linked to pulmonary hypertension, the tool aims to improve early-stage screening efficiency and provide clinicians with more precise diagnostic support.The FDA clearance marks a significant commercialization milestone for Tempus AI in the cardiovascular diagnostics space. The company, which primarily operates in precision medicine through genomic sequencing, data analytics, and clinical trial matching services, has indicated plans to further expand its AI-driven solutions across broader healthcare applications.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}